NCT06296966
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
A Four-Week, Double-Masked, Randomized, Placebo-Controlled, Phase 2, Evaluation of the Safety and Efficacy of VSJ-110 Ophthalmic Solution in the Treatment of Dry Eye
Vanda Pharmaceuticals·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Dry Eye
- Drug/Device/Intervention
- VSJ-110
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Vanda Pharmaceuticals
- Location
- Andover, United States of America
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Feb 29, 2024
- End date
- Jul 01, 2024
- Enrollment
- 40 participants
Primary outcome
Schirmer's Tear Test
Summary
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to
 placebo in the treatment of dry eye.
ICD-10 classifications
Ocular painAvulsion of eyeOther corneal deformitiesCorneal ulcerDry mouth, unspecified
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06296966
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06296966 through Pure Global AI's free database. This Phase 2 trial is sponsored by Vanda Pharmaceuticals and is currently Recruiting. The study focuses on Dry Eye. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.